BenevolentAl Therapeutics Pipeline and Triage
BenevolentAl pipeline assets target treatment of
prevalent diseases with high unmet need
Illustrative Crohn's Disease target market
239k US | 233k EU5 | 17k JP
Mod-Sev Crohn's Disease patients 20205
Global Crohn's Disease market value 20292 $11.9B
Peak sales forecast Entyvio (2025)10
(Vedolizumab, Subcut. injection, mAb, anti a4ẞ7 integrin,
launched 2014, $36,200 patient/year in US)
$4.0B WW (Crohn's disease only)
Illustrative NASH target market
Treatable NASH patients 20204
Global NASH market value 202911
Peak sales forecast Resmetirom (2026)12
(MGL-3196, oral, THRb agonist, expected launch 2022)
13.9M US | 7.8M EU5 | 4.6M JP
$27.2B
$719M WW (NASH only)
Illustrative GBM target market
Treatable GBM patients 2020³
10k US | 12k EU5 | 1.5k JP
Global GBM market value 202613
Peak sales forecast Tagrisso (2026)⁹
(osimertinib mesylate, oral, EGFR inhibitor, expected
GBM launch 2022,~$185,000 patient/year in US)
Illustrative IPF target market
Treatable IPF patients 20206
Global IPF market value 202616
Peak sales forecast Ofev (2026)17
(Nintedanib, oral, kinase inhibitor, launched 2014,
$85,500 patient/year in US)
$1.57B
$594M (GBM only)
115k US | 68.9k EU5 | 21.5k JP
$3.74B
$2.85B WW (IPF only)
Illustrative ALS target market
Treatable ALS patients 20201
Global ALS market value 202914
Peak sales forecast verdiperstat (2026) 15
(oral myeloperoxidase inhibitor, expected launch 2023)
21k US | 22k EU5 | 11k JP
$1.04B
$192M WW (ALS only)
Illustrative CKD target market
Treatable CKD patients 20207
7MM CKD market value 20268
Peak sales forecast Farxiga (2024) 18
(Dapagliflozin, oral, SGLT2 inhibitor, launched 2021,
$4,000 patient/year in US)
3.7M US | 3.1M EU5 | 1.8M JP
$10.5B
$639M WW (CKD only)
Sources: (1) Global Data Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2029, 18 September 2020; (2) GlobalData, Crohn's Disease: Global Drug Forecast and Market Analysis to 2029, calculated for the 7MM (US, EU5, JP); (3) Global Data Glioblastoma Multiforme (GBM):
Opportunity Analysis and Forecasts to 2027, 26 October 2018; (4) Global Data Non-Alcoholic Steatohepatitis: Epidemiology Forecast to 2029, 17 June 2020; (5) Global Data Crohns Disease Global Drug Forecast and Market Analysis to 2029, September 2020; (6) Idiopathic Pulmonary
Fibrosis: Epidemiology Forecast to 2029, 17 September 2020; (7) Global Data Epidemiology and Market Size Database, Chronic Kidney Disease [Accessed 29 Oct 2021]; (8) Global Data OpportunityAnalyzer: Late-Stage Chronic Kidney Disease - Opportunity Analysis and Forecasts to
2026 22 December 2017 (9) Based on use in NSCLC, Evaluate Pharma Product Report - Tagrisso [Accessed 01 Nov 2021]; (10) Evaluate Pharma Product Report - Entyvio [Accessed 01 Nov 2021]; (11) Global Data, Non-Alcoholic Steatohepatitis (NASH): Opportunity Analysis and Forecasts to
2029; (12) Evaluate Pharma Product Report - Resmetirom [Accessed 01 Nov 2021]; (13) Evaluate Pharma Indication Profile - Glioblastoma Multiforme [Accessed 29 Oct 2021]; (14) Global Data, Amyotrophic Lateral Sclerosis (ALS): Opportunity Analysis and Forecasts to 2029]; (15)
EvaluatePharma Product Report - Verdiperstat [Accessed 01 Nov 2021]; (16) Evaluate Pharma Indication Profile - Idiopathic Pulmonary Fibrosis [Accessed 29 Oct 2021]; (17) Evaluate Pharma Product Report - Ofev [Accessed 03 Nov 2021]; (18) based on pricing in Type 2 Diabetes,
Evaluate Pharma Product Report - Farxiga [Accessed 01 Nov 2021];
Al
Benevolent 72View entire presentation